TP53 and non-small cell lung carcinoma: p53 mutations, i.e. missense mutations, frameshift insertions and deletions, and point mutations, were reported to occur in approximately 50% of NSCLC and 80% of SCLC32, 33, while c-Myc mutations, i.e. DNA amplification overexpression, were more common in SCLC in up to 40% of all cases33.